BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double‐Blind Randomised Interventional Phase 2b Trial
Authors:
Open Access
- 3 March 2025
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 16 (2) , e13750
Abstract
Background: Sarcopenia is a progressive muscle disorder that may lead to mobility disability. No pharmaceutical interventions are currently available, and treatment relies on physical exercise and nutrition. The aim of SARA‐INT was to investigate whether BIO101 (20‐hydroxyecdysone), an activator of the MAS receptor, is safe and improves muscle function and physical performance of community dwelling older sarcopenic patients. Methods: SARA‐INT was a randomised three‐arm interventional study (BIO101 175 mg bid /350 mg bid/placebo) with a planned 6‐month treatment (up to 9 months in 50 subjects). Eligibility criteria for sarcopenia were meeting FNIH criteria for sarcopenia and Short Physical Performance Battery (SPPB) score ≤ 8/12 in men and women aged ≥ 65 years. Primary endpoint was the change from baseline (CFB) in gait speed (GS) measured by 400‐m walking test (400MWT), secondary endpoints being CFB in other physical performance tests. Results: A total of 233 participants were randomised (mean age 75.5 ± 7.12; 54.3% female), of whom 232 and 156 were included in the full analysis set (FAS) and per‐protocol (PP) populations, respectively. Due to COVID‐19 pandemic, 55% of on‐site end‐of‐treatment efficacy assessments were lost, reducing the studies' power. In the primary analysis (mix of 6/9 months), BIO101 350 mg bid treatment after 6/9 months was associated with an improvement in the 400MWT of 0.07 m/s versus placebo in the FAS population (not significant) and of 0.09 m/s in the PP population ( p = 0.008). BIO101 350 mg bid treatment effect on the 400MWT GS was also observed in pre‐defined subpopulations at higher risk of mobility disability (0.0474 m/s for slow walkers, 0.0521 m/s for obese and 0.0662 m/s for chair stand sub‐score ≤ 2 from SPPB in the FAS population), with a trend for a dose response. BIO101 showed a good safety profile at both doses (number of subjects with related treatment emergent adverse events (TEAEs) of 13 (16.0%), 10 (13.3%) and 10 (13.5%) in the placebo, 175 mg and 350 mg BIO101 groups, respectively). Conclusions: After 6 to 9 months of treatment, BIO101 350 mg bid showed strong trends consistent with a clinically relevant effect on the 400MWT GS, close to the minimal clinically important difference (MCID) in sarcopenia (0.1 m/s). This was also shown in predefined subpopulations at higher risk of mobility disability. BIO101 showed a good safety profile. Taken together, efficacy and safety data of this Phase 2 trial encourage us to pursue further development of BIO101 for the treatment of sarcopenia.Keywords
This publication has 40 references indexed in Scilit:
- Meaningful Improvement in Gait Speed in Hip Fracture RecoveryJournal of the American Geriatrics Society, 2011
- Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on SarcopeniaJournal of the American Medical Directors Association, 2011
- Hand‐Grip Strength Cut Points to Screen Older Persons at Risk for Mobility LimitationJournal of the American Geriatrics Society, 2010
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Effects of a Physical Activity Intervention on Measures of Physical Performance: Results of the Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) StudyThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2006
- Association of Long-Distance Corridor Walk Performance With Mortality, Cardiovascular Disease, Mobility Limitation, and DisabilityJAMA, 2006
- Meaningful Change and Responsiveness in Common Physical Performance Measures in Older AdultsJournal of the American Geriatrics Society, 2006
- Reliability of the 400‐M Usual‐Pace Walk Test as an Assessment of Mobility Limitation in Older AdultsJournal of the American Geriatrics Society, 2004
- The Healthcare Costs of Sarcopenia in the United StatesJournal of the American Geriatrics Society, 2003
- A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home AdmissionJournal of Gerontology, 1994